Dermira Stock Price, News & Analysis (NASDAQ:DERM) Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.54▼$6.8750-Day Range$18.73▼$18.8552-Week Range$5.25▼$19.48Volume536,644 shsAverage Volume185,571 shsMarket Capitalization$107.73 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestSocial MediaStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestSocial Media Dermira MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3.1% Upside$6.00 Price TargetShort InterestHealthy0.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 5 Articles This WeekInsider TradingAcquiring Shares$232,140 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.16) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.46 out of 5 starsMedical Sector881st out of 954 stocksPharmaceutical Preparations Industry336th out of 362 stocks 1.5 Analyst's Opinion Consensus RatingDermira has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Dermira has a forecasted upside of 3.1% from its current price of $5.82.Amount of Analyst CoverageDermira has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.74% of the float of Dermira has been sold short.Short Interest Ratio / Days to CoverDermira has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dermira has recently decreased by 45.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDermira does not currently pay a dividend.Dividend GrowthDermira does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DERM. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 5 news articles for Dermira this week, compared to 0 articles on an average week.Search Interest14 people have searched for DERM on MarketBeat in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.MarketBeat Follows9 people have added Dermira to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dermira insiders have bought 1,271.82% more of their company's stock than they have sold. Specifically, they have bought $232,140.00 in company stock and sold $16,922.00 in company stock.Percentage Held by Insiders19.42% of the stock of Dermira is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.95% of the stock of Dermira is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Dermira are expected to decrease in the coming year, from ($0.16) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dermira is -7.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dermira is -7.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDermira has a P/B Ratio of 6.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Dermira Stock (NASDAQ:DERM)Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology. Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.Read More DERM Stock News HeadlinesDecember 7, 2023 | finance.yahoo.com4 Growth Stocks to Buy Ahead of a Strong Year-End RallyDecember 7, 2023 | finance.yahoo.comJourney Medical (DERM) Up on Update for Skin Disease CandidateDecember 8, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.December 7, 2023 | finance.yahoo.comJourney Medical Corporation's (NASDAQ:DERM) largest shareholders are public companies who were rewarded as market cap surged US$34m last weekDecember 6, 2023 | finance.yahoo.comEmpress Therapeutics Appoints Virginia Finnerty-Brooks Chief Business OfficerNovember 30, 2023 | finance.yahoo.comAre You Looking for a Top Momentum Pick? Why Journey Medical Corporation (DERM) is a Great ChoiceNovember 29, 2023 | finance.yahoo.comWhat Makes Journey Medical Corporation (DERM) a Good Fit for 'Trend Investing'November 12, 2023 | finance.yahoo.comJourney Medical Corporation (NASDAQ:DERM) Q3 2023 Earnings Call TranscriptDecember 8, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. October 31, 2023 | finance.yahoo.comJourney Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023October 12, 2023 | finance.yahoo.comAtopic Dermatitis Market 2023 – Uncovering Global Dynamics, Geographical Segmentation, and Forecast 2023-2030September 25, 2023 | benzinga.comHyperhidrosis Treatment Market to Surpass USD 1.71 billion by 2027, Garnering 4.0% CAGR Says, Transparency Market ResearchSeptember 11, 2023 | finance.yahoo.comJourney Medical Gains 40%, Insider Trades Reap BenefitSeptember 9, 2023 | finance.yahoo.comInsider Buying: Journey Medical Corp's President & CEO Claude Maraoui Acquires 26,044 SharesSeptember 7, 2023 | finance.yahoo.comJourney Medical (DERM) & Maruho Ink Deal for Qbrexza Asia RightsAugust 23, 2023 | msn.comIf You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth NowAugust 17, 2023 | finance.yahoo.comRegulatory Affairs Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028August 8, 2023 | finance.yahoo.comJourney Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue EstimatesAugust 8, 2023 | bizjournals.comNektar Therapeutics sues Lilly for breach of contract around skin drugAugust 2, 2023 | finance.yahoo.comJourney Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023July 19, 2023 | finance.yahoo.comJourney Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023July 18, 2023 | fool.comArvinas (NASDAQ: ARVN)July 10, 2023 | finance.yahoo.comReCode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate AffairsJuly 4, 2023 | finance.yahoo.comJourney Medical (DERM) to Post Skin Disease Data, Stock Rises 26%June 22, 2023 | marketwatch.comHyperhidrosis Treatment market overview showcases immense growth potential and worth with a proper CAGR of 9.7% forcasted from 2023 to 2030June 14, 2023 | finance.yahoo.comJourney Medical (DERM) Up on Rosacea Candidate's Positive DataJune 13, 2023 | finance.yahoo.comWhy Are Journey Medical Shares Trading Higher TodaySee More Headlines Receive DERM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dermira and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DERM CUSIPN/A CIK1557883 Webwww.dermira.com Phone650-421-7200FaxN/AEmployees333Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+3.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,630,000.00 Net Margins-15.46% Pretax Margin-15.33% Return on Equity-118.05% Return on Assets-14.68% Debt Debt-to-Equity RatioN/A Current Ratio0.92 Quick Ratio0.69 Sales & Book Value Annual Sales$73.67 million Price / Sales1.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.96 per share Price / Book6.06Miscellaneous Outstanding Shares18,510,000Free Float14,914,000Market Cap$107.73 million OptionableNot Optionable Beta0.82 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Thomas G. Wiggans (Age 67)Co-Founder, CEO & Chairman Dr. Eugene Andrew Bauer (Age 77)Co-Founder, Chief Medical Officer & Director Mr. Andrew L. Guggenhime (Age 51)Chief Financial Officer Ms. Lori Lyons-Williams (Age 42)Chief Commercial Officer Mr. Christopher M. Griffith (Age 43)Co-Founder and Chief Bus. & Strategy Officer Key CompetitorsAssertioNASDAQ:ASRTGlycoMimeticsNASDAQ:GLYCSelecta BiosciencesNASDAQ:RNACAnnovis BioNYSE:ANVSKinnate BiopharmaNASDAQ:KNTEView All CompetitorsInsidersJeffrey PaleySold 1,745 sharesTotal: $9,108.90 ($5.22/share)Jeffrey PaleySold 2,245 sharesTotal: $7,812.60 ($3.48/share)Justin Adam SmithBought 33,000 shares on 10/13/2023Total: $98,340.00 ($2.98/share)Jeffrey PaleyBought 15,000 shares on 10/6/2023Total: $44,700.00 ($2.98/share)Jeffrey PaleyBought 30,000 shares on 9/21/2023Total: $89,100.00 ($2.97/share)View All Insider Transactions DERM Stock Analysis - Frequently Asked Questions Should I buy or sell Dermira stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DERM shares. View DERM analyst ratings or view top-rated stocks. What is Dermira's stock price target for 2024? 1 equities research analysts have issued 1-year target prices for Dermira's shares. Their DERM share price targets range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 3.1% from the stock's current price. View analysts price targets for DERM or view top-rated stocks among Wall Street analysts. Are investors shorting Dermira? Dermira saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 44,600 shares, a decrease of 45.2% from the October 31st total of 81,400 shares. Based on an average trading volume of 99,300 shares, the short-interest ratio is currently 0.4 days. Approximately 0.7% of the shares of the stock are sold short. View Dermira's Short Interest. When is Dermira's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our DERM earnings forecast. How were Dermira's earnings last quarter? Dermira Inc (NASDAQ:DERM) released its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.96. The biopharmaceutical company earned $34.54 million during the quarter, compared to analyst estimates of $16.88 million. Dermira had a negative net margin of 15.46% and a negative trailing twelve-month return on equity of 118.05%. What other stocks do shareholders of Dermira own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dermira investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Novavax (NVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), Karyopharm Therapeutics (KPTI), Pfizer (PFE), AT&T (T), Exelixis (EXEL) and ImmunoGen (IMGN). When did Dermira IPO? (DERM) raised $39 million in an initial public offering on Friday, November 12th 2021. The company issued 3,520,000 shares at a price of $10.00-$12.00 per share. This page (NASDAQ:DERM) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermira Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.